Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases
V Chaudhry, DR Cornblath, JW Griffin, R O'brien… - Neurology, 2001 - AAN Enterprises
V Chaudhry, DR Cornblath, JW Griffin, R O'brien, DB Drachman
Neurology, 2001•AAN EnterprisesThe authors report the use mycophenolate mofetil (MM) in the treatment of neuromuscular
diseases. Thirty-eight patients (32 with MG, three with inflammatory myopathy, and three
with chronic acquired demyelinating neuropathy) were treated with MM for an average
duration of 12 months. All patients tolerated MM without major side effects. Twenty-four
patients improved either in their functional status or in their ability to reduce corticosteroid
dose. Mean time to improvement was 5 months.
diseases. Thirty-eight patients (32 with MG, three with inflammatory myopathy, and three
with chronic acquired demyelinating neuropathy) were treated with MM for an average
duration of 12 months. All patients tolerated MM without major side effects. Twenty-four
patients improved either in their functional status or in their ability to reduce corticosteroid
dose. Mean time to improvement was 5 months.
The authors report the use mycophenolate mofetil (MM) in the treatment of neuromuscular diseases. Thirty-eight patients (32 with MG, three with inflammatory myopathy, and three with chronic acquired demyelinating neuropathy) were treated with MM for an average duration of 12 months. All patients tolerated MM without major side effects. Twenty-four patients improved either in their functional status or in their ability to reduce corticosteroid dose. Mean time to improvement was 5 months.
American Academy of Neurology